Skip to main content
TipRanks
Go Ultimate75% OFF

Viatris (0A5V) AI Stock Analysis

0 Followers
GB:0A5V

Viatris

(LSE:0A5V)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Strong Cash GenerationConsistently positive free cash flow gives Viatris internal funding for debt service, reinvestment, dividends, and selective business development. This cash-generation capacity remains valuable even while reported net income is negative, supporting financial resilience and ongoing capital allocation.
Negative Factors
Revenue Decline and Net LossesThe multi-year revenue downtrend and continuing net losses indicate that Viatris has not yet converted its broad portfolio into consistent bottom-line earnings. Although EBITDA and losses improved, sustained profitability still depends on stabilizing sales and maintaining operating discipline.

Viatris (0A5V) vs. iShares MSCI United Kingdom ETF (EWC)

-25%0%25%50%75%100%125%GB:0A5V+108.12%EWC+17.53%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$23.78B
Dividend Yield
2.31%
Average Volume (3M)
7,159
Price to Earnings (P/E)
-39.0
Beta (1Y)
0.90
Revenue Growth
4.80%
EPS Growth
82.97%
Country
UK
Employees
30,000
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Viatris Business Overview & Revenue Model

Company Description

Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company...

Viatris Earnings Call Summary

Earnings Call Date:Nov 05, 2026(Q3-2026)|% Change Since:8.16%|Next Earnings Date:Mar 01, 2027
Earnings Call SentimentPositive

The call was strongly positive overall. Viatris reported solid Q3 and nine-month financial growth, raised 2026 guidance, highlighted accelerating North American growth, continued Greater China momentum, strong cash flow, substantial pipeline progress, and expected benefits from the proposed Pacira acquisition. These positives outweighed challenges from Nashik-related supply constraints, policy-driven China moderation, regional declines, competition, and upcoming loss-of-exclusivity impacts.

Positive Updates

Strong Third-Quarter and Year-to-Date Financial Performance
Q3 total revenues were $3.75 billion, adjusted EBITDA was $1.2 billion, and adjusted EPS was $0.71 per share. Through the first nine months, total revenues grew 2%, adjusted EBITDA grew 6%, and adjusted EPS grew 8% operationally versus the prior year.

Negative Updates

Nashik Remediation and Supply Constraints
Supply constraints, primarily related to remediation activities at the Nashik facility, affected Europe and emerging markets. The revenue impact was approximately $100 million in Q3. In September, the FDA classified the plant as Official Action Indicated following May 483 observations, and Viatris suspended manufacturing there in October while remediation continues.

Company Guidance

For 2026, excluding contributions from the proposed acquisition of Pacira, Viatris expects at the midpoint of its revised guidance ranges operational growth of approximately 2% for total revenues, 6% for adjusted EBITDA and 8% for adjusted EPS versus the prior year; by region, North America is expected to be in the high single-digit range, Europe flattish, emerging markets and JANZ low single-digit declines, and Greater China closer to the low double-digit range, while fourth-quarter supply disruptions are expected to impact total revenues by approximately $100 million, and net savings from the strategic review are expected to reach $120 million this year. Viatris expects the Pacira transaction to close before the end of November, be immediately accretive to all financial guidance metrics in 2027 versus expected 2026 results, generate more than $50 million in annual cost synergies by the end of 2028, and help its U.S. innovative medicines business generate more than $1 billion in total revenue in 2027; Greater China is expected to grow in 2027, albeit closer to historical averages in the low to mid-single-digit range, and the company expects its patches to reach 1.5 million women in 2026 and add in 2027 another 1 million of women using its patches.

Viatris Risk Analysis

Viatris disclosed 18 risk factors in its most recent earnings report. Viatris reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

1 New Risk
1.We may not complete the proposed acquisition of Pacira within the timeframe we anticipate or at all and, if completed, we may not realize the anticipated benefits, synergies and operating efficiencies of the proposed acquisition.Q3, 2026

Viatris Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

GB:0A5V against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
RDYRDY66Neutral$12.26B41.017.37%0.76%-10.52%-55.45%
TEVATEVA65Neutral$50.90B100.239.18%―2.99%-28.63%
AMRXAMRX58Neutral$7.40B49.43131.71%―8.88%2272.07%
PRGOPRGO52Neutral$2.25B-1.27-68.13%7.17%-4.45%-3289.03%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
ALVOALVO43Neutral$1.72B-5.5397.21%―-14.25%-417.72%

* Healthcare Sector Average

Performance Comparison

0%50%100%GB:0A5VRDYPRGOTEVAAMRXALVODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
GB:0A5V and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
GB:0A5VViatris, Inc.20.6010.44102.76%
RDYDr. Reddy's Laboratories Ltd14.790.825.85%
PRGOPerrigo Company15.764.0434.53%
TEVATeva Pharmaceutical Industries Limited42.6216.6263.92%
AMRXAmneal Pharma21.129.6083.33%
ALVOAlvotech4.37-0.86-16.44%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.